Citations

Clear

2429 citation(s) found for "Shah, SS".

Harnessing next-generation informatics for personalizing medicine: a report from AMIA’s 2014 Health Policy Invitational Meeting
Wiley, Laura K. , Tarczy‐Hornoch, Peter , Denny, Joshua C. , Freimuth, Robert R. , Overby, Casey Lynnette, Martin, Ross D., Taylor, Casey Overby , Shah, Nigam H. , Sarkar, Indra Neil , Denny, Joshua C , Freimuth, Robert R , Wiley, Laura K

Mayo Clinic

Journal of the American Medical Informatics Association | February 6, 2016 | Volume: 23 | Issue: 2 | Pages: 413-419

10.1093/jamia/ocv111 | PMID 26911808 Get It

Abstract The American Medical Informatics Association convened the 2014 Health Policy Invitational Meeting to develop recommendations for updates to current policies and to establish an informatics research agenda for personalizing medicine. In particular, the meeting focused on discussing informatics challenges related to personalizing care through the integration of genomic or other high-volume biomolecular data with data from clinical systems to make health care more efficient and effective. This report summarizes the findings ( n = 6) and recommendations ( n = 15) from the policy meeting, which were clustered into 3 broad areas: (1) policies governing data access for research and personalization of care; (2) policy and research needs for evolving data interpretation and knowledge representation; and (3) policy and research needs to ensure data integrity and preservation. The meeting outcome underscored the need to address a number of important policy and technical considerations in order to realize the potential of personalized or precision medicine in actual clinical contexts.
The Method for Performance Measurement Matters: Diabetes Care Quality as Measured by Administrative Claims and Institutional Registry
Tulledge‐Scheitel, Sidna M. , Naessens, James M. , Glasgow, Amy E. , Stroebel, Robert J. , Crane, Sarah J. , Bunkers, Kari S., Shah, Nilay D. , Glasgow, Amy E. , Tulledge-Scheitel, Sidna M, McCoy, Rozalina G. , Glasgow, Amy E

Mayo Clinic

Health Services Research | February 5, 2016 | Volume: 51 | Issue: 6 | Pages: 2206-2220

10.1111/1475-6773.12453 | PMID 26846443 Get It

ObjectivesPerformance measurement is used by health care providers, payers, and patients. Historically accomplished using administrative data, registries are used increasingly to track and improve care. We assess how measured diabetes care quality differs when calculated using claims versus registry.Data Sources/Study SettingCross‐sectional analysis of administrative claims and electronic health records (EHRs) of patients in a multispecialty integrated health system in 2012 (n = 368,883).Study DesignWe calculated percent of patients attaining glycohemoglobin <8.0 percent, LDL cholesterol <100 mg/dL, blood pressure <140/90 mmHg, and nonsmoking (D4) in cohorts, identified by Medicare Accountable Care Organization/Minnesota Community Measures (ACO‐MNCM; claims‐based), Healthcare Effectiveness Data and Information Set (HEDIS; claims‐based), and registry (EHR‐based).Data Collection/Extraction MethodsClaims were linked to EHR to create a dataset of performance‐eligible patients.Principal FindingsACO‐MNCM, HEDIS, and registry identified 6,475, 6,989, and 6,425 measurement‐eligible patients. Half were common among the methods; discrepancies were due to attribution, age restriction, and encounter requirements. D4 attainment was lower in ACO‐MNCM (36.09 percent) and HEDIS (37.51 percent) compared to registry (43.74 percent) cohorts.ConclusionsRegistry‐ and claims‐based performance measurement methods identify different patients, resulting in different rates of quality metric attainment with implications for innovative population health management.
Bilateral Foot Gangrene
Stopsack, Konrad H. , Vinod Shah, Mithun, Shah, Meera , Stopsack, Konrad H

Mayo Clinic

JAMA Oncology | February 5, 2016 | Volume: 2 | Issue: 3 | Pages: 387

10.1001/jamaoncol.2015.6156 | PMID 26847423 Get It

Diabetes-Associated Variation in TCF7L2 Is Not Associated With Hepatic or Extrahepatic Insulin Resistance
Varghese, Ron T. , Viegas, Iván , Barosa, Cristina , Marques, Catía , Rizza, Robert A., Jones, John G. , Shah, Mithun V , Vella, Adrian

Mayo Clinic

Diabetes | January 29, 2016 | Volume: 65 | Issue: 4 | Pages: 887-892

10.2337/db15-1593 | PMID 26822092 Get It

A common genetic variation in TCF7L2 is associated with type 2 diabetes. However, the mechanism by which this occurs remains elusive. In addition to affecting insulin secretion, genetic variation at the TCF7L2 locus may alter insulin action or directly modify hepatic glucose metabolism. We sought to determine whether the diabetes-associated variant in this locus (the T allele of rs7903146) increases fasting endogenous glucose production (EGP), and impairs insulin-induced suppression of EGP and insulin-stimulated glucose disappearance. To address this, we studied individuals who were either homozygous for the diabetes-associated allele (TT) at rs7903146 or were homozygous for the protective allele (CC). Subjects were matched for other anthropometric characteristics and were studied using a euglycemic clamp. EGP and glucose uptake were measured using the tracer dilution technique, and the relative contribution of gluconeogenesis to EGP was quantitated using deuterated water corrected for transaldolase exchange. We report that the diabetes-associated variation in TCF7L2 did not associate with fasting EGP, insulin-induced suppression of EGP, and insulin-induced stimulation of glucose uptake. There was no association with the contribution of gluconeogenesis and glycogenolysis to EGP. These data indicate that genetic variation at TCF7L2 does not predispose an individual to type 2 diabetes by altering either hepatic or extrahepatic insulin action.
Modeling GATAD1-Associated Dilated Cardiomyopathy in Adult Zebrafish
Yang, Jingchun , Shah, Sahrish, Olson, Timothy M. , Xu, Xiaolei

Mayo Clinic

Journal of Cardiovascular Development and Disease | January 26, 2016 | Volume: 3 | Issue: 1 | Pages: 6

10.3390/jcdd3010006 | PMID 28955713 Get It

Animal models have played a critical role in validating human dilated cardiomyopathy (DCM) genes, particularly those that implicate novel mechanisms for heart failure. However, the disease phenotype may be delayed due to age-dependent penetrance. For this reason, we generated an adult zebrafish model, which is a simpler vertebrate model with higher throughput than rodents. Specifically, we studied the zebrafish homologue of GATAD1, a recently identified gene for adult-onset autosomal recessive DCM. We showed cardiac expression of gatad1 transcripts, by whole mount in situ hybridization in zebrafish embryos, and demonstrated nuclear and sarcomeric I-band subcellular localization of Gatad1 protein in cardiomyocytes, by injecting a Tol2 plasmid encoding fluorescently-tagged Gatad1. We next generated gatad1 knock-out fish lines by TALEN technology and a transgenic fish line that expresses the human DCM GATAD1-S102P mutation in cardiomyocytes. Under stress conditions, longitudinal studies uncovered heart failure (HF)-like phenotypes in stable KO mutants and a tendency toward HF phenotypes in transgenic lines. Based on these efforts of studying a gene-based inherited cardiomyopathy model, we discuss the strengths and bottlenecks of adult zebrafish as a new vertebrate model for assessing candidate cardiomyopathy genes.
Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database
Renfro, Lindsay A. , Allegra, Carmen J. , André, Thierry , Gramont, Aimery de , Haller, Daniel G. , Yothers, Greg , Shah, Manish A, de Gramont, Aimery, Schmoll, Hans‐Joachim , Shah, Manish A , Alberts, Steven R. , Sargent, Daniel J. , André, Thierry , Yothers, Greg

Mayo Clinic

Journal of Clinical Oncology | January 26, 2016 | Volume: 34 | Issue: 8 | Pages: 843-853

10.1200/jco.2015.63.0558 | PMID 26811529 Get It

Purpose Fluorouracil plus leucovorin (FU + LV) adjuvant chemotherapy reduced the risk of recurrence and death across all time points in a pooled analysis of 20,898 patients with colon cancer from 18 randomized studies. The impact of oxaliplatin added to FU + LV on the time course of recurrence and survival remains unknown. Patients and Methods A total of 12,233 patients enrolled to the randomized trials C-07, C-08, N0147, MOSAIC (Adjuvant Treatment of Colon Cancer), and XELOXA (Adjuvant XELOX) were pooled to examine the impact of oxaliplatin and tumor-specific factors on the time course of recurrence and death. For each end point, continuous-time risk was modeled over 6 years post treatment in all oxaliplatin-treated patients and patients concurrently randomized to FU + LV with or without oxaliplatin; the latter analyses supported time-dependent treatment comparisons. Results Addition of oxaliplatin significantly reduced the risk of recurrence within the first 14 months post treatment for patients with stage II disease and within the first 4 years for patients with stage III disease. Oxaliplatin also significantly reduced risk of death from 2 to 6 years post treatment for patients with stage III disease, with no differences in timing of outcomes between treatment groups (ie, oxaliplatin did not simply postpone recurrence or death compared with FU + LV alone). Patients with stage II disease receiving oxaliplatin did not exhibit a significant reduction in risk of death in the first 6 years post treatment. Recurrence risk peaked near 14 months for both treatments, and risk of recurrence and death increased with increased tumor and nodal burden. Conclusions These analyses support the addition of oxaliplatin to fluoropyrimidine-based adjuvant therapy in patients with stage III disease and underscore the need for adequate surveillance of patients with colon cancer during the first 3 years after adjuvant therapy.
Uptake and Documentation of the Use of an Encounter Decision Aid in Usual Practice
Inselman, Jonathan , Castañeda-Guarderas, Ana, Gionfriddo, Michael R. , Zeballos‐Palacios, Claudia , Shah, Nilay D. , Montori, Víctor M. , Branda, Megan, Zeballos-Palacios, Claudia L, Morris, Megan M, LeBlanc, Annie , Branda, Megan E. , Morris, Megan M. , Montori, Victor M

Mayo Clinic

Medical Decision Making | December 31, 2015 | Volume: 36 | Issue: 4 | Pages: 557-561

10.1177/0272989x15618175 | PMID 26721257 Get It

Southwestern Aging and Geriatrics Education Scholars: Effectiveness of a Geriatrics Education Innovative Small Grants Program
Kirk, Lynne M. , Shah, Amit , Rubin, Craig D. , Shah, Amit A, Shah, Amit A

Mayo Clinic

Journal of the American Geriatrics Society | December 22, 2015 | Volume: 63 | Issue: 12 | Pages: 2624-2625

10.1111/jgs.13844 | PMID 26691701 Get It

In reference to “national cohort study of opioid analgesic dose and risk of future hospitalization”
Sundaragiri, Pranathi R., Vallabhajosyula, Saraschandra , Shah, Neel , Shah, Neel B, Vallabhajosyula, Saraschandra

Mayo Clinic

Journal of Hospital Medicine | November 23, 2015 | Volume: 11 | Issue: 2 | Pages: 155-156

10.1002/jhm.2514 | PMID 26595452 Get It

Hail to the chief—Keith Lindor, our new AASLD president
Shah, Vijay H. , Gores, G. J., LaRusso, Nick F., Gores, Greg J

Mayo Clinic

Hepatology | November 14, 2015 | Volume: 63 | Issue: 2 | Pages: 357-359

10.1002/hep.28342 | PMID 26566704 Get It